

UNITED STATES DISTRICT COURT

DISTRICT OF NEW JERSEY

(609) 989-2040

CHAMBERS OF

TONIANNE J. BONGIOVANNI
UNITED STATES MAGISTRATE JUDGE

U.S. COURTHOUSE
402 E. STATE STREET, RM 6052
TRENTON, NJ 08608

June 25, 2015

LETTER ORDER

Re: AstraZeneca AB, et al. v. Mylan Laboratories Limited, et al.
Civil Action No. 12-1378 (MLC)

Dear Counsel:

During the course of this litigation the Court has discussed with the parties the possibility of Defendants pursuing an at risk launch. The Court is aware that Defendants will be eligible for final FDA approval of their generic drug on August 3, 2015. While Defendants have not informed the Court that they definitively intend to pursue an at risk launch, the Court is aware that there will be no impediments to them doing so come August. As a result, in order to afford the parties a reasonable opportunity to brief a preliminary injunction motion and in order to afford the District Court a fair opportunity to consider same, the Court sets the following briefing schedule:

Date	Event
July 9, 2015	AstraZeneca moves for preliminary injunction
July 20, 2015	Defendants oppose AstraZeneca's motion
July 24, 2015	AstraZeneca replies to Defendants' opposition
TBD	Oral argument (if required)
August 3, 2015	Defendants' eligibility for final FDA approval

To the extent the Court can assist the parties in avoiding the aforementioned motion practice, they are directed to contact the undersigned immediately.

IT IS SO ORDERED.

s/ Tonianne J. Bongiovanni
TONIANNE J. BONGIOVANNI
United States Magistrate Judge